Progress on UK biosimilars is under threat

12 October 2022
biologic_biosimilar_lab_large

An Expert View from Mark Samuels, chief executive, British Biosimilars Association.

Biosimilars are among the UK National Health Service's (NHS) most crucial medicines. They are essential for supporting patient access to treatments while helping the NHS to remain affordable, yet biosimilars’ future is under threat in the UK.

The progress in biosimilar adoption in this country is a story built on collaboration, and in a few short years, the UK went from lagging to leading in terms of take-up compared to other parts of Europe.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biosimilars